![]() |
Name |
Musaolide D
|
Molecular Formula | C12H20O3 | |
IUPAC Name* |
3-hexan-2-yl-4-(methoxymethyl)-2H-furan-5-one
|
|
SMILES |
CCCCC(C)C1=C(COC)C(=O)OC1
|
|
InChI |
InChI=1S/C12H20O3/c1-4-5-6-9(2)10-8-15-12(13)11(10)7-14-3/h9H,4-8H2,1-3H3
|
|
InChIKey |
YTAQIKAJJPSCKR-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 212.29 | ALogp: | 2.3 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 35.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.635 |
Caco-2 Permeability: | -4.558 | MDCK Permeability: | 0.00002010 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.01 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.038 |
30% Bioavailability (F30%): | 0.022 |
Blood-Brain-Barrier Penetration (BBB): | 0.867 | Plasma Protein Binding (PPB): | 95.56% |
Volume Distribution (VD): | 3.162 | Fu: | 6.34% |
CYP1A2-inhibitor: | 0.484 | CYP1A2-substrate: | 0.864 |
CYP2C19-inhibitor: | 0.041 | CYP2C19-substrate: | 0.316 |
CYP2C9-inhibitor: | 0.136 | CYP2C9-substrate: | 0.308 |
CYP2D6-inhibitor: | 0.077 | CYP2D6-substrate: | 0.586 |
CYP3A4-inhibitor: | 0.028 | CYP3A4-substrate: | 0.211 |
Clearance (CL): | 9.327 | Half-life (T1/2): | 0.791 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.129 |
Drug-inuced Liver Injury (DILI): | 0.055 | AMES Toxicity: | 0.03 |
Rat Oral Acute Toxicity: | 0.939 | Maximum Recommended Daily Dose: | 0.095 |
Skin Sensitization: | 0.353 | Carcinogencity: | 0.911 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.106 |
Respiratory Toxicity: | 0.945 |